根治性前列腺切除术后挽救性放疗前PSMA-PET阴性扫描的预后意义
这项回顾性多中心分析纳入300例根治性前列腺切除术后生化复发且PSMA-PET阴性的患者,评估挽救性放疗的结局。中位随访33个月,3年生化复发无生存率、无转移生存率和总生存率分别为73.9%、87.8%和99.1%。PSMA-PET前PSA≤0.5 ng/ml与>0.5 ng/ml患者的3年bRFS分别为77.5%和48.3%,作者认为数据支持对PSMA-PET阴性患者早期行挽救性放疗。
要点
- 根治性前列腺切除术后生化复发且PSMA-PET阴性者,挽救性放疗后3年bRFS为73.9%。
- PSMA-PET前PSA≤0.5 ng/ml者3年bRFS为77.5%,>0.5 ng/ml者为48.3%。
- 多因素分析中精囊侵犯、ISUP评分>2和挽救性放疗前PSA>0.5 ng/ml与更差bRFS显著相关。
核心结论
- 根治性前列腺切除术后生化复发且PSMA-PET阴性的患者接受挽救性放疗可获得较好的生化复发无生存率。
- 作者认为这些数据支持对PSMA-PET阴性发现的患者使用早期挽救性放疗。
研究设计与样本
- 回顾性、多中心(11个中心、5个国家)分析,纳入根治性前列腺切除术后生化复发且PSMA-PET分期无疾病证据后接受挽救性放疗的患者。
- 共纳入300例患者,253例(84.3%)仅接受前列腺床挽救性放疗,46例(15.3%)额外接受选择性盆腔淋巴结照射。
- 仅41例(13.7%)接受同期雄激素剥夺治疗(ADT)。
- 采用Kaplan-Meier法评估生化复发无生存率(bRFS)、无转移生存率(MFS)和总生存率(OS),采用多因素Cox比例风险回归评估预设的生存结局预测因素。
主要发现
- 挽救性放疗后中位随访33个月(IQR:20-46个月)。
- 挽救性放疗后3年bRFS、MFS和OS分别为73.9%、87.8%和99.1%。
- PSMA-PET前PSA≤0.5 ng/ml与>0.5 ng/ml患者的3年bRFS分别为77.5%和48.3%。
- 单因素分析中,ISUP分级>2(p=0.006)、手术时盆腔淋巴结转移(p=0.032)、精囊侵犯(p<0.001)、挽救性放疗前PSA>0.5 ng/ml(p=0.004)和未同期接受ADT(p=0.023)与更差bRFS显著相关。
- 多因素Cox比例风险回归中,精囊侵犯(p=0.007)、ISUP评分>2(p=0.048)和挽救性放疗前PSA>0.5 ng/ml(p=0.013)仍与更差bRFS显著相关。
临床怎么用
- 作者认为这些数据支持对PSMA-PET阴性发现的患者使用早期挽救性放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The optimal management for early recurrent prostate cancer following radical prostatectomy (RP) in patients with negative prostate-specific membrane antigen positron-emission tomography (PSMA-PET) scan is an ongoing subject of debate. The aim of this study was to evaluate the outcome of salvage radiotherapy (SRT) in patients with biochemical recurrence with negative PSMA PET finding. METHODS: This retrospective, multicenter (11 centers, 5 countries) analysis included patients who underwent SRT following biochemical recurrence (BR) of PC after RP without evidence of disease on PSMA-PET staging. Biochemical recurrence-free survival (bRFS), metastatic-free survival (MFS) and overall survival (OS) were assessed using Kaplan-Meier method. Multivariable Cox proportional hazards regression assessed predefined predictors of survival outcomes. RESULTS: Three hundred patients were included, 253 (84.3%) received SRT to the prostate bed only, 46 (15.3%) additional elective pelvic nodal irradiation, respectively. Only 41 patients (13.7%) received concomitant androgen deprivation therapy (ADT). Median follow-up after SRT was 33 months (IQR: 20-46 months). Three-year bRFS, MFS, and OS following SRT were 73.9%, 87.8%, and 99.1%, respectively. Three-year bRFS was 77.5% and 48.3% for patients with PSA levels before PSMA-PET ≤ 0.5 ng/ml and > 0.5 ng/ml, respectively. Using univariate analysis, the International Society of Urological Pathology (ISUP) grade > 2 (p = 0.006), metastatic pelvic lymph nodes at surgery (p = 0.032), seminal vesicle involvement (p < 0.001), pre-SRT PSA level of > 0.5 ng/ml (p = 0.004), and lack of concomitant ADT (p = 0.023) were significantly associated with worse bRFS. On multivariate Cox proportional hazards, seminal vesicle infiltration (p = 0.007), ISUP score >2 (p = 0.048), and pre SRT PSA level > 0.5 ng/ml (p = 0.013) remained significantly associated with worse bRFS. CONCLUSION: Favorable bRFS after SRT in patients with BR and negative PSMA-PET following RP was achieved. These data support the usage of early SRT for patients with negative PSMA-PET findings.
引用
- Adebahr S, Althaus A, Scharl S, et al. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37736808. doi:10.1007/s00259-023-06438-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。